Klotho Neurosciences Appeals Nasdaq Delisting Decision, Seeks to Maintain Compliance

As previously reported, on August 16, 2024, Klotho Neurosciences, Inc. (the "Company") received two delinquency notification letters (the "Notices") from the Nasdaq Stock Market LLC ("Nasdaq") due to the Company's non-compliance with Nasdaq Listing Rules 5450(b)(2)(C) and 5450(b)(2)(A). The Notices cite the Company's (a) not being in compliance with the minimum Market Value of Publicly Held Shares ("MVPHS") requirement as set forth in Nasdaq Listing Rule 5450(b)(2)(C) and (b) not being in compliance with the minimum Market Value of Listed Securities ("MVLS") requirement as set forth in Nasdaq Listing Rule 5450(b)(2)(A). The Notices provided that in accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company was given 180 calendar days, or until February 12, 2025, to regain compliance with the MVPHS and MVLS standards.

On February 14, 2025, the Company received written notice (the "Delisting Notice") from the Nasdaq Listing Qualifications Department stating that the Company has not regained compliance with the Rules and the Company's securities will be delisted from The Nasdaq Global Markets (the "Delisting Determination") unless the Company requests an appeal of this determination by February 21, 2025 pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series.

On February 21, 2025, the Company exercised its right to request a hearing to appeal the Delisting Determination and paid Nasdaq the applicable fee (the "Hearing Request"). The Hearing Request stays the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision.